Firefly Neuroscience (AIFF) EBT (2010 - 2026)

Firefly Neuroscience's EBT history runs 16 years deep, the most recent figure standing at -$2.0 million for Q1 2026.

• On a quarterly basis, EBT rose 84.5% year-over-year to -$2.0 million in Q1 2026; TTM through Mar 2026 was -$9.0 million, a 61.27% increase from a year earlier, with the FY2025 full-year figure at -$19.9 million, down 90.07% from the prior year.
• EBT climbed to -$2.0 million in Q1 2026 per AIFF's latest filing, from -$2.5 million in the prior quarter.
• Across five years, EBT topped out at $456438.0 in Q2 2023 and bottomed at -$12.9 million in Q1 2025.
• The 5-year median for EBT is -$1.7 million (2022), against an average of -$2.5 million.
• Across the five-year window, EBT tumbled 3851.17% in 2022 and surged 128.19% in 2023, its largest moves.
• Year by year, EBT stood at -$1.0 million in 2022, then decreased by 4.32% to -$1.1 million in 2023, then plunged by 520.35% to -$6.7 million in 2024, then surged by 62.86% to -$2.5 million in 2025, then gained by 19.16% to -$2.0 million in 2026.
• Per Business Quant, the three latest AIFF EBT figures stand at -$2.0 million (Q1 2026), -$2.5 million (Q4 2025), and -$2.6 million (Q3 2025).